IGY Life Sciences announces the closing of $12.8 million (CDN) in new funding to meet high product demandigyadmin2023-07-11T20:12:57+00:00March 24th, 2023|Read More
IGY Life Sciences achieves 94.8% purity of IgY, opening the way for large-scale health applications for Nutraceuticalsigyadmin2023-07-11T20:13:36+00:00September 7th, 2022|Read More
IGY Life Sciences Partners with MMS Holdings to Develop Novel COVID-19 Antibody Treatmentigyadmin2023-07-11T20:14:38+00:00June 8th, 2020|Read More
